Literature DB >> 23139025

[New treatment strategies for male lower urinary tract symptoms].

L F Arenas da Silva1, M Schönthaler, F Cruz, C Gratzke, J Zumbe, A Stenzl, B Amend, K-D Sievert.   

Abstract

For patients with lower urinary tract symptoms (LUTS), α1-adrenoreceptor inhibitors and 5-alpha reductase inhibitors as well as their combination are considered the gold standard. In addition, anticholinergic agents are being introduced as monotherapy or in combination with α1-adrenocepetor inhibitors for patients with predominant storage disorders. Phosphodiesterase 5 (PDE5) inhibitors are often the best option for patients with LUTS who also suffer from erectile dysfunction. Recently, novel treatment options have been presented and intraprostatic injection of various agents, such as botulinum toxin A, NX-1207 and PRX302 has shown promising initial results. In addition, innovative minimally invasive treatment options, such as UroLift® appear to be efficacious and safe in this patient cohort. Particular emphasis should be laid on patients with LUTS and concomitant sexual disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23139025     DOI: 10.1007/s00120-012-3032-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  48 in total

Review 1.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

2.  Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells.

Authors:  Clara Crescioli; Mario Maggi; Michaela Luconi; Gabriella Barbara Vannelli; Roberto Salerno; Antonio A Sinisi; Lorella Bonaccorsi; Pietro Ferruzzi; Tullio Barni; Gianni Forti; Mario Serio
Journal:  Prostate       Date:  2002-01-01       Impact factor: 4.104

3.  Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting.

Authors:  Amy E Krambeck; Debra J Jacobson; Michaela E McGree; Deborah J Lightner; Michael M Lieber; Steven J Jacobsen; Jennifer L St Sauver
Journal:  BJU Int       Date:  2012-04-03       Impact factor: 5.588

4.  Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial.

Authors:  William C W Wong; Eliza L Y Wong; Han Li; Joyce H You; Suzanne Ho; Jean Woo; Elsie Hui
Journal:  J Altern Complement Med       Date:  2012-01       Impact factor: 2.579

5.  Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings.

Authors:  M J Hyman; A Groutz; J G Blaivas
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

6.  Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Authors:  Henry H Woo; Peter T Chin; Thomas A McNicholas; Harcharan S Gill; Mark K Plante; Reginald C Bruskewitz; Claus G Roehrborn
Journal:  BJU Int       Date:  2011-05-06       Impact factor: 5.588

7.  BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.

Authors:  Enrico Colli; Patrizio Rigatti; Francesco Montorsi; Walter Artibani; Stefano Petta; Nicola Mondaini; Roberto Scarpa; Paolo Usai; Lorenza Olivieri; Mario Maggi
Journal:  Eur Urol       Date:  2005-11-15       Impact factor: 20.096

8.  LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.

Authors:  Ferenc G Rick; Andrew V Schally; Norman L Block; Gabor Halmos; Roberto Perez; Jesus B Fernandez; Irving Vidaurre; Luca Szalontay
Journal:  Prostate       Date:  2010-10-13       Impact factor: 4.104

9.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

10.  Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.

Authors:  Ravibhushan Singh; Jeff L Browning; Ralph Abi-Habib; Kevin Wong; Simon A Williams; Rosemina Merchant; Samuel R Denmeade; Thomas J Buckley; Arthur E Frankel
Journal:  Anticancer Drugs       Date:  2007-08       Impact factor: 2.248

View more
  5 in total

1.  Ahead of the curve.

Authors:  David B Nash
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

2.  [Intraprostatic injection therapy in patients with benign prostatic syndrome].

Authors:  T Bschleipfer; T Bach; C Gratzke; S Madersbacher; M Oelke
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

3.  Effect of an employer-sponsored health and wellness program on medical cost and utilization.

Authors:  Hangsheng Liu; Katherine M Harris; Sarah Weinberger; Seth Serxner; Soeren Mattke; Ellen Exum
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

4.  [UroLift®: an operative non-ablative procedure for treatment of benign prostatic syndrome].

Authors:  R Berges; K D Sievert; C Gratzke; U Wetterauer
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

5.  [Urinary incontinence in the elderly: what can and should be done?].

Authors:  B Amend; S Kruck; J Bedke; R Ritter; L Arenas da Silva; C Chapple; A Stenzl; K-D Sievert
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.